Migraines

Although exacerbation of UC usually poses little diagnostic dilemma, physicians should remain cognizant to the possibility of an alternative cause for patient symptoms. An article published in the World Journal of Gastroenterology addresses this report. The research team led by Prof.

More: continued here

Children who suffer from bouts of allergic rhinitis (hay fever) are also more likely to suffer from headaches, facial pain, and ear aches than children without these allergies, says new research presented at the 2008 American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO in Chicago, IL. Allergic rhinitis is a collection of symptoms predominantly in the nose and eyes, caused by airborne particles of dust, dander, or plant pollens.

More: continued here

The Migraine Research Foundation (MRF), the largest nonprofit funder of migraine research in the United States, today announced the winners of its second round of grants intended to spur innovation in migraine research. The grants totaled $200,000. The grantees were screened by MRF’s medical advisory board, which is composed of leading scientists and clinicians from across the country.

More: continued here

People with migraines may also be more likely to develop blood clots in their veins, according to a study published in the September 16, 2008, issue of Neurology®, the medical journal of the American Academy of Neurology. In the condition, called venous thrombosis or thromboembolism, blood clots form in a vein, which can limit blood flow and cause swelling and pain. Those clots can then dislodge from the vein and travel to the heart and the lungs, which can be fatal.

More: continued here

Doctors need to pay special attention to people with migraine with aura as they could be at increased risk of stroke or heart attack, a London conference heard today. Professor Tobias Kurth, a leading neuroepidemiologist from Harvard Medical School, USA, has found the links between migraine with aura and cardiovascular events are now so strong that GPs need to take them seriously.

More: continued here

Merck Sharp & Dohme Limited announced that in a Phase III clinical trial telcagepant (formerly known as MK-0974) - an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist - significantly relieved moderate-to-severe migraine attacks, including migraine pain and migraine-associated symptoms, compared to placebo. In addition, the overall rates of adverse events in this trial were similar for telcagepant and placebo.

More: continued here

CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally Acting Anti- Migraine Agent (NAAMA), which unlike triptans, exhibits anti-migraine activity without causing vasoconstriction.

More: continued here

Results from a new pooled data analysis presented at the European Headache and Migraine Trust International Congress (EHMTIC) 2008 today show that zolmitriptan (’Zomig’) nasal spray provided fast and efficacious relief in the treatment of episodic and chronic cluster headache.

More: continued here

NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, today announced data from its Pilot Efficacy Study of its Oral Spray formulation of sumatriptan (Sumatriptan OS) compared to sumatriptan tablets, marketed as Imitrex®/Imigran®, the leading triptan indicated for the treatment of migraine headaches.

More: continued here